Bespak is a specialist inhalation contract development and manufacturing organisation (CDMO) focused on pulmonary and nasal drug delivery. Trusted by the world’s leading pharmaceutical companies, ...
PARMA, Italia & HOLMES CHAPEL, Regno Unito-- (BUSINESS WIRE)--mar 11, 2026-- Chiesi, azienda biofarmaceutica internazionale ...
Bespak is increasing pressurized metered dose inhaler manufacturing capacity to support Chiesi Group’s Carbon Minimal Inhaler (CMI) program.
DevPro Biopharma and Bespak have announced the completion of early feasibility studies on DP007, a new formulation of albuterol in a pressurized metered dose inhaler (pMDI) which shows comparable ...
LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ...
LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, ...
Switching asthma patients from a pressurised metered dose inhaler (pMDI) to a dry powder inhaler (DPI) for maintenance therapy more than halves their carbon footprint without loss of asthma control, ...
Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results